Cheteh, Emarndeena H.
Sarne, Victoria
Ceder, Sophia
Bianchi, Julie
Augsten, Martin
Rundqvist, Helene
Egevad, Lars
Ăstman, Arne
Wiman, Klas G.
Funding for this research was provided by:
Cancerfonden (18 0774)
VetenskapsrÄdet (2017-01509)
Radiumhemmets Forskningsfonder (171213)
Article History
Received: 20 March 2020
Revised: 27 April 2020
Accepted: 29 April 2020
First Online: 2 June 2020
Conflict of interest
: K.G.W. is co-founder and shareholder of Aprea Therapeutics, a company that develops novel p53-based cancer therapy including APR-246. K.G.W. is a member of its Clinical Advisory Board. K.G.W. has received research support and salary from Aprea Therapeutics. The other authors declare no conflict of interest.